文献速递免疫规划传染病防控与疫情报告

AV7909炭疽疫苗候选两剂间隔两周在豚鼠和非人灵长类中的效力

Efficacy of the AV7909 anthrax vaccine candidate in guinea pigs and nonhuman primates following two immunizations two weeks apart.
PubMed 文献 · Vaccine · 2020-11-13

AV7909是下一代暴露后预防吸入性炭疽的候选疫苗。本研究显示0、2周两剂方案在首次免疫后第28天和第70天保护豚鼠和非人灵长类抵抗致死性吸入性炭疽攻击,且比已批准AVA的0、2、4周方案更早诱导保护性毒素中和抗体水平。

要点

  • 0、2周两剂AV7909在豚鼠和非人灵长类中诱导针对吸入性炭疽的保护。
  • 保护作用在首次免疫后第28天和第70天攻击时均观察到。
  • 该方案可能比已批准AVA的0、2、4周方案更早产生保护性抗体。

核心结论

  • 0、2周两剂AV7909方案可保护豚鼠和非人灵长类抵抗致死性吸入性炭疽攻击。

研究设计与样本

  • 研究在豚鼠和非人灵长类中评估0、2周两剂AV7909的效力,攻击时间为首次免疫后第28天和第70天。

主要发现

  • 0、2周AV7909方案在首次免疫后第28天和第70天保护豚鼠和非人灵长类抵抗致死性吸入性炭疽攻击。
  • 临床研究中0、2周或0、4周两剂AV7909诱导的免疫应答优于BioThrax®(AVA)。
  • 先前报道0、4周AV7909方案首次免疫后第70天炭疽毒素中和抗体水平与动物保护相关。

临床怎么用

  • 0、2周AV7909方案可能较已批准AVA的0、2、4周暴露后预防方案更早诱导保护性毒素中和抗体。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The anthrax vaccine candidate AV7909 is being developed as a next-generation vaccine for post-exposure prophylaxis (PEP) against inhalational anthrax. In clinical studies, two vaccinations with AV7909 administered either two or four weeks apart induced an enhanced immune response compared to BioThrax® (Anthrax Vaccine Adsorbed) (AVA). Anthrax toxin-neutralizing antibody (TNA) levels on Day 70 following initial vaccination that were associated with protection of animals exposed to inhalational anthrax were previously reported for the 0, 4-week AV7909 vaccination regimen. The current study shows that a 0, 2-week AV7909 vaccination regimen protected guinea pigs (GPs) and nonhuman primates (NHPs) against a lethal inhalational anthrax challenge on Days 28 and 70 after the first immunization. An earlier induction of protective TNA levels using a 0, 2-week AV7909 vaccination regimen may provide benefit over the currently approved AVA PEP 0, 2, and 4-week vaccination regimen.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Shearer JD, Henning L, Sanford DC, et al. Efficacy of the AV7909 anthrax vaccine candidate in guinea pigs and nonhuman primates following two immunizations two weeks apart. Vaccine. 2020. PMID: 33199078. doi:10.1016/j.vaccine.2020.10.095

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。